APOE-stratified genome-wide association analyses provide insights into the genetic etiology of Alzheimers's disease.
- Open access
APOE-stratified GWAS reveal novel genetic signals for Alzheimer's disease, with DDHD1 showing protective effects specifically in APOE ε4 carriers.
- Why it matters: Understanding how APOE variants influence Alzheimer's risk is crucial for developing targeted therapies and improving treatment efficacy, especially given the limited success of current anti-amyloid approaches.
- What they did: The study conducted genome-wide association analyses stratified by APOE ε4 and ε2 carrier status, identifying new risk loci such as HP1BP3, SLC50A1, and DDHD1, which are linked to disease mechanisms.
- The result: Findings highlight APOE-specific genetic factors that could inform personalized treatment strategies, enhance clinical trial design, and advance mechanism-based therapies for neurodegenerative diseases.